These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29941909)

  • 21. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
    Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
    Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of an osteomyelitis case caused by dalbavancin, ceftaroline, and vancomycin non-susceptible methicillin-resistant Staphylococcus aureus.
    Dahdouh E; Díaz-Pollán B; Falces-Romero I; Mingorance J; Gómez-Gil R
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):2029-2032. PubMed ID: 33686556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.
    Lingscheid T; Poeppl W; Bernitzky D; Veletzky L; Kussmann M; Plasenzotti R; Burgmann H
    Antimicrob Agents Chemother; 2015 Feb; 59(2):859-63. PubMed ID: 25403675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-biofilm activity of dalbavancin against methicillin-resistant
    Silva V; Miranda C; Bezerra M; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    J Chemother; 2021 Nov; 33(7):469-475. PubMed ID: 33904369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
    Koeth LM; DiFranco-Fisher JM; McCurdy S
    J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis.
    Karau MJ; Schmidt-Malan SM; Albano M; Mandrekar JN; Rivera CG; Osmon DR; Oravec CP; Berry DJ; Abdel MP; Patel R
    J Infect Dis; 2020 Oct; 222(9):1498-1504. PubMed ID: 32914837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new small animal model for simulating a two-stage-revision procedure in implant-related methicillin-resistant Staphylococcus aureus bone infection.
    Brunotte M; Rupp M; Stötzel S; Sommer U; Mohammed W; Thormann U; Heiss C; Lips KS; Domann E; Alt V
    Injury; 2019 Nov; 50(11):1921-1928. PubMed ID: 31451184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of clinical evidence for dalbavancin].
    Rodríguez-Pardo D
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
    Yin LY; Calhoun JH; Thomas TS; Wirtz ED
    J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.
    Park KH; Greenwood-Quaintance KE; Mandrekar J; Patel R
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6568-6572. PubMed ID: 27550347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
    Petrakis V; Panagopoulos P; Papanas N
    Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
    Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of linezolid, teicoplanin, and vancomycin in prevention of an experimental polytetrafluoroethylene graft infection model caused by methicillin-resistant Staphylococcus aureus.
    Mese B; Bozoglan O; Elveren S; Eroglu E; Gul M; Celik A; Ciralik H; Yildirimdemir HI; Yasim A
    Med Sci Monit; 2015 Mar; 21():909-14. PubMed ID: 25819685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intra-Articular Vancomycin Powder Eliminates Methicillin-Resistant S. aureus in a Rat Model of a Contaminated Intra-Articular Implant.
    Edelstein AI; Weiner JA; Cook RW; Chun DS; Monroe E; Mitchell SM; Kannan A; Hsu WK; Stulberg SD; Hsu EL
    J Bone Joint Surg Am; 2017 Feb; 99(3):232-238. PubMed ID: 28145954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.